胃肠道出血患者恢复抗血栓治疗的影响:多中心回顾性队列研究
1Department of Gastroenterology, Xuanwu Hospital Capital Medical University, Changchun Street 45#, 100053 Beijing, China.
Therapeutic advances in gastroenterology
|June 11, 2025
概括
对胃肠道出血的抗血栓治疗减少了28天的死亡率,但显著增加了再次出血的风险. 早期恢复这些疗法也可能增加死亡风险.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃肠道出血 (GIB) 是一种严重的疾病,死亡率高.
- 增加抗血栓剂 (抗血小板,抗凝剂) 的使用与GIB发病率上升相关.
研究的目的:
- 调查抗血栓治疗对GIB患者28天死亡率和再出血的影响.
- 为了比较与不同抗血栓剂和恢复时间相关的风险.
主要方法:
- 以后视的队列研究,使用来自三个独立数据库的数据 (2008-2022年).
- 倾向性得分匹配和治疗权重的逆概率 (IPTW) 控制混因素.
- 权重后勤回归分析了抗血小板,抗凝固剂和组合疗法子组的结果.
主要成果:
- 抗血栓治疗与28天死亡率显著降低相关 (8.2%对12.5%).
- 然而,抗血栓治疗显著增加了复出出血率 (19.9%对10.5%) 和风险 (OR=2.118).
- 抗凝剂或组合治疗显示出最高的复出风险;早期恢复 (3天内) 增加了死亡风险.
结论:
- 抗血栓治疗提供了一个权衡:降低死亡率,但增加了GIB的再出血风险.
- 由于风险增加,需要仔细考虑特定药物 (抗凝剂,组合疗法) 和早期恢复时间.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Esophageal Varices-II: Clinical Features and Management
50
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
50
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118


